RJA
ELAN icon

Raymond James & Associates’s Elanco Animal Health ELAN Stock Holding History

Raymond James & Associates’s Portfolio ELAN Stock Details ELAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$6.81M Sell
463,504
-777,405
-63% -$10.8M ﹤0.01% 1444
2024
Q2 		$17.9M Buy
1,240,909
+28,436
+2% +$454K 0.01% 833
2024
Q1 		$19.7M Sell
1,212,473
-2,059
-0.2% -$32.2K 0.01% 784
2023
Q4 		$18.1M Buy
1,214,532
+199,238
+20% +$2.26M 0.01% 782
2023
Q3 		$11.4M Buy
1,015,294
+688,779
+211% +$8M 0.01% 968
2023
Q2 		$3.28M Buy
326,515
+251,708
+336% +$2.34M ﹤0.01% 1761
2023
Q1 		$703K Buy
74,807
+4,677
+7% +$55.2K ﹤0.01% 2697
2022
Q4 		$857K Buy
70,130
+895
+1% +$11.2K ﹤0.01% 2526
2022
Q3 		$859K Sell
69,235
-148,627
-68% -$2.6M ﹤0.01% 2501
2022
Q2 		$4.28M Buy
217,862
+24,573
+13% +$582K ﹤0.01% 1498
2022
Q1 		$5.04M Sell
193,289
-791,994
-80% -$21.1M ﹤0.01% 1505
2021
Q4 		$28M Buy
985,283
+25,223
+3% +$785K 0.02% 589
2021
Q3 		$30.6M Buy
960,060
+90,909
+10% +$3.05M 0.03% 519
2021
Q2 		$30.2M Sell
869,151
-227,481
-21% -$7.5M 0.03% 514
2021
Q1 		$32.3M Buy
1,096,632
+88,881
+9% +$2.73M 0.03% 456
2020
Q4 		$30.9M Buy
1,007,751
+271,085
+37% +$8.27M 0.03% 443
2020
Q3 		$20.6M Buy
736,666
+220,665
+43% +$5.59M 0.03% 525
2020
Q2 		$11.1M Sell
516,001
-52,993
-9% -$1.17M 0.01% 777
2020
Q1 		$12.7M Buy
568,994
+195,428
+52% +$5.35M 0.02% 641
2019
Q4 		$11M Buy
373,566
+45,207
+14% +$1.23M 0.01% 860
2019
Q3 		$8.73M Buy
328,359
+126,124
+62% +$3.78M 0.01% 921
2019
Q2 		$6.84M Buy
202,235
+5,210
+3% +$169K 0.01% 1064
2019
Q1 		$6.32M Buy
197,025
+129,229
+191% +$3.98M 0.01% 1065
2018
Q4 		$2.14M Buy
67,796
+7,407
+12% +$243K ﹤0.01% 1614
2018
Q3 		$2.11M Buy
+60,389
New +$2.12M ﹤0.01% 1782

Other funds holding ELAN

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SCM
Shapiro Capital Management Atlanta, Georgia $1.65B AUM 26.74% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Raymond James & Associates's ELAN Position: Q3 2024 in Review

Raymond James & Associates reduced its Elanco Animal Health (ELAN) stake by 63% in Q3 2024, selling an estimated $10.8M and leaving 463,504 shares worth $6.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Raymond James & Associates first reported a position in ELAN in Q3 2018 and has held it in 25 quarters since. The position peaked at $32.3M in Q1 2021. 388 funds tracked by Wall St. Rank hold ELAN as of Q3 2024.

  • Raymond James & Associates held 463,504 shares of Elanco Animal Health worth $6.81M as of Q3 2024.
  • Raymond James & Associates sold 777,405 Elanco Animal Health shares in Q3 2024, an estimated $10.8M.
  • Elanco Animal Health made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1444 holding.
  • Raymond James & Associates first reported a position in Elanco Animal Health in Q3 2018 and has held it in 25 quarters since.
  • Raymond James & Associates's Elanco Animal Health position peaked at $32.3M in Q1 2021.
  • 388 funds tracked by Wall St. Rank held Elanco Animal Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.